HFSA Virtual Board Certification Review 2021
Welcome to the HFSA Virtual Board Certification Review course! The course will comprise of OnDemand webinars, live Q&A Panels, and bonus features. Please take some time to review the information below to help maximize your virtual meeting experience.
Each livestream session opens 15 minutes prior to the start time. To attend a session, click the "Livestream Sessions" tab and select the desired session.
You will also have access to the recordings of the sessions offered with your registration. Recordings will be posted approximately 24-48 hours after the session concludes. To access the OnDemand and archived session recordings, click the "OnDemand" tab.
To access all currently available presentation slides, click the "Presentations Slides" tab. Check back frequently for updated materials. You will also be able to access course resources (ex. Question Bank, Reading List) in the "Attendee Resources" tab.
Want to continue a conversation after a session or discuss questions in the Question Bank? Participate in conversations with fellow course attendees and faculty here.
Learn more about HFSA's Gold Corporate Members by clicking the "HFSA Gold Corporate Members" tab.
Note: Attendees will leave the accredited educational component of the meeting. Clicking any of the links under each company listing will result in leaving the event platform.
Attendees will receive an exclusive invitation to attend a virtual post-meeting, virtual livestream Q&A panel taking place on October 1, 2021 at 3 PM ET. This is an opportunity for attendees to ask last-minute questions prior to the ABIM AHFTC Maintenace of Certification Exam on October examination on October 14, 2021. You will receive an email a week prior to the event with a link to access the event.
The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year’s HFSA Virtual Board Certification Review Course: Abbott; AstraZeneca Pharmaceuticals; Alnylam Pharmaceuticals; Cytokinetics; Medtronic; Merck